Literature DB >> 2307548

A distribution-free procedure for the statistical analysis of bioequivalence studies.

D Hauschke1, V W Steinijans, E Diletti.   

Abstract

In bioequivalence assessment, the consumer risk of erroneously accepting bioequivalence is of primary concern. In order to control the consumer risk, the decision problem is formulated with bioinequivalence as hypothesis and bioequivalence as alternative. In the parametric approach, a split into two one-sided test problems and application of two-sample t-tests have been suggested. Rejection of both hypotheses at nominal alpha-level is equivalent to the inclusion of the classical (shortest) (1-2 alpha) 100%-confidence interval in the bioequivalence range. This paper demonstrates that the rejection of the two one-sided hypotheses at nominal alpha-level by means of nonparametric Mann-Whitney-Wilcoxon tests is equivalent to the inclusion of the corresponding distribution-free (1-2 alpha) 100%-confidence interval in the bioequivalence range. This distribution-free (nonparametric) approach needs weaker model assumptions and hence presents an alternative to the parametric approach.

Mesh:

Year:  1990        PMID: 2307548

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  36 in total

1.  Comparative bioavailability of two immediate release tablets of enalapril/hydrochlorothiazide in healthy volunteers.

Authors:  Manuela T Maya; Nuno J Goncalves; Nuno E Silva; Augusto E P Filipe; José A Morais; M C Caturla; M Rovira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Apr-Jun       Impact factor: 2.441

2.  Pharmacokinetics of the active metabolite of the prodrug repirinast in healthy Caucasian volunteers after a single oral dose.

Authors:  D Beermann; H G Schaefer; M Wargenau; B Heibel; Y Sturm; J Kuhlmann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.

Authors:  Walter Dieterle; Sophie Corynen; Jessica Mann
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

4.  Estimation of Cmax and Tmax in populations after single and multiple drug administrations.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-10       Impact factor: 2.745

Review 5.  Pharmacokinetic characterization of controlled-release formulations.

Authors:  V W Steinijans
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

6.  Statistical aspects of bioequivalence testing between two medicinal products.

Authors:  E Zintzaras
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

Review 7.  Controversies in bioequivalence studies.

Authors:  V W Steinijans; D Hauschke; J H Jonkman
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

8.  Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study.

Authors:  G Suarez-Kurtz; F A Bozza; F L Vicente; C G Ponte; C J Struchiner
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

9.  Considerations in the attainment of steady state: aggregate vs. individual assessment.

Authors:  W W Hauck; T N Tozer; S Anderson; F Y Bois
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

10.  Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects.

Authors:  D Rosillon; A Stockis; G Poli; D Acerbi; R Lins; B Jeanbaptiste
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.